DeepCure announced on July 25 that the initial clinical trial cases of its laparoscopic-based renal denervation (RDN) system, HyperQure™, have been published in JACC: Case Reports, the official journal under the American College of Cardiology (ACC).
The paper introduced the outstanding therapeutic outcomes of HyperQure RDN procedures through the first two cases involving patients with resistant hypertension currently being conducted in Korea. There were no adverse effects for three months following the laparoscopic RDN procedure. In the first case, the 24-hour systolic blood pressure decreased from 140 millimeters of mercury (mmHg) to 104 mmHg, a reduction of 36 mmHg. In the second case, it decreased from 199 mmHg to 104 mmHg, a reduction of 95 mmHg. Furthermore, these results were achieved after reducing the number of antihypertensive medications to three and four, respectively, following the procedure, indicating a significant effect.
This outcome far surpasses the efficacy of existing intravascular RDN devices approved by the US Food and Drug Administration (FDA), such as Medtronic's 'Spyral' and Recor Medical's 'Paradise.' In the initial 2-3 months of clinical trials for these devices, the 24-hour systolic blood pressure reductions were limited to 5.4 mmHg and 8.5 mmHg, respectively. In comparison, HyperQure demonstrates superior blood pressure-lowering effects and safety, providing important quantitative data to support its efficacy.
JACC: Case Reports is one of the JACC series published by the American College of Cardiology, and is a prestigious international journal that selectively publishes only innovative and educational clinical cases. The journal serves as a reference for guideline development and clinical practice, and is recognized as an influential academic platform by cardiology, hypertension, and interventional procedure experts worldwide.
HyperQure is a laparoscopic surgical medical device developed over approximately ten years under the leadership of Professor Changwook Jung at Seoul National University Hospital. It overcomes the limitations of conventional intravascular approaches and presents a new alternative with extravascular RDN.
DeepCure is currently conducting clinical trials for patients with resistant hypertension in both Korea and the United States, having received approval in both countries. In Korea, the clinical trial is in its final stages, while in the United States, trials are actively underway at a total of five major university hospitals.
This publication in an international journal is seen as more than a simple case report; it marks an opportunity to highlight HyperQure's global scalability, technological reliability, and potential to change the paradigm of hypertension treatment within the international cardiovascular medical community.
A DeepCure representative stated, "The publication of these initial clinical case results in an international journal objectively recognizes that HyperQure's efficacy is overwhelmingly superior to existing intravascular approaches," adding, "Based on quantitative data from clinical trials in Korea and the United States, we will accelerate our entry into the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
